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Abstract
Objective: Autonomous cortisol secretion (ACS) is a condition with ACTH-independent 
cortisol overproduction from adrenal incidentalomas (AI) or adrenal hyperplasia. The 
hypercortisolism is often mild, and most patients lack typical clinical features of overt 
Cushing’s syndrome (CS). ACS is not well defined and diagnostic tests lack validation.
Methods: Retrospective study of 165 patients with AI evaluated clinically and by assay 
of morning plasma ACTH, late-night saliva cortisol, serum DHEA sulphate (DHEAS), 24-h 
urine-free cortisol, and cortisol after dexamethasone suppression.
Results: Patients with AI (n = 165) were diagnosed as non-functioning incidentalomas 
(NFI) (n = 82) or ACS (n = 83) according to current European guidelines. Late-night saliva 
cortisol discriminated poorly between NFI and ACS, showing a high rate of false-positive 
(23/63) and false-negative (38/69) results. The conventional low-dose dexamethasone 
suppression test (LDDST) did not improve the diagnostic specificity, compared with the  
1 mg overnight DST. Receiver operating characteristic curve analysis of DHEAS in the two 
cohorts demonstrated an area under the curve of 0.76 (P < 0.01) with a sensitivity for 
ACS of 58% and a specificity of 80% using the recommended cutoff at 1.04 µmol/L  
(40 µg/dL). 
Conclusion: We here demonstrate in a large retrospective cohort of incidentaloma patients, 
that neither DHEAS, late-night saliva cortisol nor 24-h urine free cortisol are useful to 
discriminate between non-functioning adrenal incidentalomas and ACS. The conventional 
LDDST do not add further information compared with the 1 mg overnight DST. Alternative 
biomarkers are needed to improve the diagnostic workup of ACS.
Introduction
Autonomous cortisol secretion (ACS) is usually caused 
by adrenal adenomas or hyperplasia and is frequently 
diagnosed in patients with adrenal incidentalomas (AI). 
AI are adrenal masses discovered on imaging undertaken 
for other reasons than suspicion of adrenal disease and are 
found in about 3% of people at 50 years of age, with the 
prevalence increasing to up to 10% in elderly above 70 
years of age (1). Most AI are benign and non-functioning, 
that is, they do not cause excess hormone production. 
However, recent studies show that up to 30% have some 
degree of cortisol overproduction, depending on the 
diagnostic criteria applied (2).
Due to large inter- and intraindividual biological 
variation of cortisol secretion, most patients with 
ACS shows serum cortisol levels in the normal range; 
however, the diurnal and ultradian variation of cortisol 
secretion is dysregulated. Also, these patients lack the 
classical phenotype of overt Cushing syndrome (CS). 
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Formerly known as subclinical CS, ACS has a much 
higher prevalence than overt CS, affecting up to 2% of 
the adult population (3). Despite the suspected link 
between subclinical and overt CS, evidence suggests that 
progression to overt CS is rare (1). Even though typical 
clinical findings of overt CS are lacking, patients with ACS 
often show one or more components of the metabolic 
syndrome (hypertension, type 2 diabetes mellitus, 
obesity and/or dyslipidemia). These findings indicate an 
increased risk of cardiovascular morbidity and mortality 
(4, 5). Moreover, ACS is associated with low bone 
density and osteoporosis (6, 7). The European Society of 
Endocrinology (ESE) and the European Network for the 
Study of Adrenal Tumours (ENS@T) guidelines for AI (1) 
have therefore recommended that all patients with AI 
should be assessed for ACS.
The most recent international guidelines recommend 
the 1 mg overnight dexamethasone suppression test 
(DST) to screen for ACS (1). This test is not optimal, as 
the DST has low diagnostic specificity (80%) yielding 
many false-positive test results. The use of oral estrogens 
and low dexamethasone bioavailability (because of poor 
absorption or fast metabolism) are the most important 
sources of error, although the latter can be overcome by 
parallel assay of dexamethasone in the morning sample 
(8). Plasma ACTH can be an add-on test to validate the 
ACTH-independent nature of the cortisol excess. This 
test has low diagnostic accuracy and precision due to 
analytical cross-reactivity and interference, especially in 
the lower range of measurements (9, 10).
Saliva cortisol (sa-cortisol) drawn at late night is 
commonly used in the diagnostics of overt CS, but is not 
found useful to reveal low graded cortisol overproduction. 
Sa-cortisol and the 48-h conventional low-dose (0.5 mg 
four times daily) dexamethasone suppression test (LDDST) 
are not well validated in the setting of ACS, and none of 
them are recommended in the ESE/ENS@T guidelines (1). 
Twenty-four-hour urine-free cortisol (UFC), a gold standard 
in the diagnosis of overt CS, is not sensitive to diagnose 
patients with ACS. Finally, dehydroepiandrosterone 
(DHEA) and its sulphated derivate (DHEAS) make up 
the majority of androgen precursors secreted from zona 
reticulata in the adrenal cortex. DHEAS has a longer half-
life than p-ACTH, and the secretion is low or suppressed 
when ACTH is suppressed. Thus, DHEAS has the potential 
to be a more stable marker of adrenal hypercortisolism 
than p-ACTH (11, 12).
How the various diagnostic tests perform in the 
diagnosis of AI have been evaluated mostly in small 
insufficiently powered studies. Here, we checked the 
performance of these tests in an adequately sized patient 
cohort in a ‘real-life’ clinical setting.
Patients and methods
Study population
We retrospectively reviewed patients referred for 
evaluation of AI at the tertiary endocrine centers at 
Haukeland and Akershus University hospitals in Norway 
from June 2012 to August 2018. The patients in the study 
were collected consecutively from June 2012 to august 
2016. After that, only patients with ACS were included 
in our biobank/registry. The participants were evaluated 
according to ESE and ENS@T guidelines (1). Patients 
diagnosed with pheochromocytomas (n = 3), primary 
aldosteronism (n = 1) and adrenocortical carcinomas 
(n = 1) were excluded. The study cohort consisted of the 
remaining patients (n = 165), and categorised as having 
either non-functioning incidentalomas (NFI, n = 82) 
or ACS (n = 83). The ESE guidelines recognise three 
categories of patients based on post DST cortisol levels. 
S-cortisol below 50 nmol/l is named NFI, between 50 and 
139 nmol/L is named possible ACS and 140 nmol/L or 
above is ACS. We have defined ACS here as a s-cortisol 
value above 50 nmol/L after the 1 mg overnight DST 
(positive test). This because we have excluded the most 
common reasons for a false DST, namely patients with low 
dexamethasone bioavailability < 3.3 nmol/L (n = 5) (8), 
and patients using oral estrogens. In addition, all patients 
had a p-ACTH analysed and were also asked to obtain two 
late-night saliva samples for sa-cortisol. If the DST was 
positive, the patients underwent a 24 h UFC measurement 
and a LDDST. One patient with adrenal incidentaloma 
was diagnosed with pituitary CS and excluded.
Assay of hormones
S-cortisol were assayed by an in-house LCMS/MS method, 
previously described in detail (13). The reference range 
was 120–600 nmol/L for samples drawn before 10:00 h 
(14). The assay precision was 4.5–7.4% relative standard 
deviations (RSD), and the accuracy ranged from 97 to 
101% (13). DHEAS was analysed by chemiluminescent 
immunoassay (CLIA) using Siemens Immulite 2000 XPi. 
Age and gender-specific reference ranges for the method 
are given in Table 1. Intraindividual biological variation 
was estimated to be 6.35% and the analytical precision 
was RSD 9% at concentration level 12 µmol/L (15). 
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DHEAS was included in the routine diagnostic workup of 
patients with AI from January 2015. Thus, some patients 
included before this date lack data on DHEAS. Saliva was 
collected by an oral swab (Salivette, Sarstedt, Germany) 
held in the mouth for about 2 min at 23:00 h. Patients 
were instructed not to eat, brush their teeth, smoke, chew 
tobacco or use snuff for at least 1 h before sample taking. 
The samples were analysed using LCMS/MS. Positive 
tests were defined as sa-cortisol > 2.8 nmol/L, which is 
the well-validated cutoff level used for diagnosing overt 
CS at our laboratory. The analytical precision was RSD 
9% at concentration 3.1 nmol/L (16). P-ACTH samples 
were collected between 08:00 and 09:00 h, analysed by 
CLIA using Siemens Immulite 2000 XPi. Intraindividual 
biological variation was estimated to be 15%. The lower 
limit of quantification was 1.1 pmol/L and the reference 
range was 2.0–11.6 pmol/L in samples drawn before 
10:00 h. The analytical precision was RSD 8 at a 
concentration of 4 pmol/L (17). Urine was collected over 
a period of 24 h, and analysed using LCMS/MS. The 
concentration of the excreted-free cortisol was calculated 
relative to the amount of urine produced. A normal test 
was defined as a cortisol level below 165 nmol/24 h, a 
well-validated cutoff level used to diagnose overt CS at 
this method. Analytical precision was RSD 10% at a 
140 nmol/L concentration (18).
Statistics
Categorical data are given as number (%) and continuous 
data as median (range). Since the data was not normally 
distributed, non-parametric statistics were applied. A 
significance level of 0.05% was chosen. The Mann–
Whitney U-test was used to compare groups. Spearman 
correlation was used to evaluate the degree of correlation 
when appropriate. A receiver operating characteristic 
(ROC) curve was made for DHEAS and sa-cortisol to 
evaluate the diagnostic performance, and for DHEAS also 
to evaluate the proposed cutoff of 1.04 µmol/L (40 µg/dL) 
in the diagnostics of ACS (11).
Ethics
The study was approved by the local ethics committee 
(REK) and all participants signed an informed consent 
form (REK no: 2011/1810 and 2014/2170).
Results
Patient characteristics
One hundred and sixty-five patients were included in 
the study; 82 had NFI, and 83 had ACS (Table 2). Overall, 
patients with ACS had more cardiovascular risk factors 
than those with NFI. They were more often treated with 
anti-hypertensive medication and lipid-lowering drugs, 
and had a higher prevalence of type 2 diabetes mellitus 
and osteoporosis despite being less obese (Table 2).
Diagnostic testing of the cohort
The results of the diagnostic tests performed in the two 
groups of patients are summarised in Table 3. ACTH was 
assayed in plasma, and measurements were available 
in 74 of the 83 ACS patients, and in 61 of the 82 NFI 
patients. The median p-ACTH was 1.65 pmol/L (range, 
<1.1-5.5 pmol/L) and 3.9 pmol/L (range <1.1–40.2 pmol/L) 
in the ACS and NFI groups, respectively (P < 0.05). The 
median s-cortisol after DST was 84 nmol/L (range 51–486) 
in the ACS group, and 31 nmol/L (range 12–50) in the 
NFI group.
Saliva cortisol
In the ACS group, we had valid saliva data for 69/83 
patients, 14/69 patients had one saliva sample performed 
and 55/69 patients had two. In the NFI group, 63/82 
patients had valid saliva data, one saliva sample was 
obtained in 12/63 patients and 51/63 patients delivered 
two samples. The median sa-cortisol level was higher in 
the ACS than in the NFI group (1.75 nmol/L (0.4–45) vs 
0.9 nmol/L (0.1–8.2); P < 0.05) even though both medians 
were below the cutoff for a normal test (2.8 nmol/L). Thirty-
eight of sixty-nine patients in the ACS group and 40/63 
in the NFI group had normal saliva samples. However, in 
patients who delivered two saliva samples, 16/55 in the 
ACS group and 4/51 with NFI had one positive and one 
Table 1 Age- and sex-adjusted reference range for DHEAS 
(μmol/L).
Age, years Sex Lower limit (μmol/L) Upper limit (μmol/L)
18–29 Female 1.5 11.6
Male 2.2 13.5
30–39 Female 1.6 11.0
Male 2.1 11.6
40–49 Female 0.7 7.8
Male 1.5 9.7
>50 Female 0.4 4.9
50–60 Male 1.1 11.5
>60 Male 0.4 5.4
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negative measurement (Fig. 1). In the ACS group, 30/55 
patients with two samples tested negative in both (two 
false-negative tests), while 11/51 in the NFI group had two 
positive tests (two false-positive tests) (Fig. 1). There were 
no significant differences in the proportions of positive 
and negative saliva test results between patients with post 
DST cortisol above and below 140 nmol/L. A receiver 
operating characteristic (ROC) curve for late-night saliva 
cortisol as a marker of ACS showed a low area under the 
curve (AUC) of 0.65 (CI 0.58–0.72, P < 0.05), and there 
were not possible to derive a better cutoff level than 2.8 
nmol/L, suitable to differentiate between ACS and NFI.
Dehydroepiandrosterone sulphate
In the ACS group, we had valid DHEAS data for 58/83 
patients, and in the NFI group 54/82 patients. The median 
value of DHEAS was 0.95 µmol/L (range <0.4–3.8 µmol/L) 
in the ACS group, compared to 1.85 µmol/L (range 
<0.4–10.5, P < 0.001) in the NFI group. A proposed cutoff 
for DHEAS in the diagnostics of ACS is 1.04 µmol/L 
(40 µg/dL), using the exact same method as our laboratory 
(11). In the ACS group, 32/38 patients had DHEAS 
measurements equal to or below this cutoff compared to 
11/54 patients in the NFI group. There were no significant 
difference between median post DST cortisol (33 nmol/L) 
in patients with NFI and low DHEAS, compared to those 
with NFI and DHEAS above 1.04 µmol/L (30 nmol/L). 
There were no significant differences in the proportions 
of patients with DHEAS above and below 1.04 µmol/L 
between patients with post DST cortisol above and below 
140 nmol/L. Figure 2 demonstrates a ROC curve for DHEAS 
as a marker for ACS with an area under the curve (AUC) 
of 0.76 (CI 0.68–0.85, P < 0.05). Applied to our cohort, 
the cutoff of 1.04 µmol/L (40 µg/dL) yields a sensitivity of 
58% and a specificity 80% for diagnosing ACS. 
Dennedy  et  al. have suggested to calculate a ratio 
derived by dividing DHEAS by the lower limit of the sex- 
and age-specific reference range for the analysis. We used 
the recommended lower limits shown in Table 1 for the 
Table 2 Characteristics of the subjects in the study.
NFI (n = 82) ACS (n = 83)
Women, n (%) 48 (56.1) 58 (69.9)
Age, median, years (range)  68.5 (33–82) 65 (29–86)
BMI, median, kg/m2 (range) 28.6 (18.3–42.6) 26.1 (16.4–45.2)
Hypertension, n (%)a 42 (50.9) 54 (64.8)
Diabetes type II, n (%)a 7 (8.5) 14 (16.7)
HbA1c, median, % (range) 5.7 (5–9) 5.8 (5–9)
Treatment for dyslipidemia, n (%)a 16 (19.5) 18 (21.7)
Osteoporosis, n (%)a 7 (8.5) 15 (18.1)
Creatinine, median, µmol/L (range) 75 (40–138) 72 (39–971)
Smokers, n (%)a 31 (37.8) 30 (36.1)
Unilateral AI, n (%) 66 (81.0) 66 (79.2)
Size of unilateral AI, median, mm (range) 22 (9–70) 24 (10–51)
Bilateral AI, n (%) 16 (19.0) 17 (20.8)
Size of largest AI if bilateral, median, mm (range) 28 (13–45) 33 (21–42)
Categorical data are given as number and percent, continuous data as median and range. In the case of bilateral AI, only the largest of the two lesions 
was included when calculating median size and range.
aSignificant difference between the NFI and the ACS group. P < 0.05.
Table 3 Results of diagnostic testing.
NFI ACS
Basal cortisol, median, nmol/L (range)a 320 (110–629) 411 (130–985)
Morning ACTH, median, pmol/L (range)a 3.9 (1.1–40.2) 1.65 (1.1–5.5)
Cortisol after 1 mg DST, median, nmol/L (range)a 31.0 (12–50) 84 (51–486)
Late-night saliva cortisol, median, nmol/L (range)a 0.9 (0.1–8.2) 1.75 (0.4–45)
DHEAS, median, µmol/L, (range)a 1.85 (0.4–10.5) 0.95 (0.4–3.8)
UFC, median, nmol/24 h (range) 72 (2–321)
LDDST, median, nmol/L (range) 89 (58–517)
Continuous data as median and range. Lower limit of quantification for p-ACTH, s-cortisol after DST and s-DHEAS was put as registered value for all 
patients who tested below the limit (<1.1 pmol/L, <28 nmol/L and <0.4 µmol/L for p-ACTH, s-cortisol after DST and s-DHEAS, respectively).
aSignificant difference between the NFI and the ACS group.
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ratio calculations (12). We found a median DHEAS ratio 
significantly lower in the ACS group (1.75, CI 1.0–9.5), 
compared to the NFI group (3.0, CI 0.26–26.5, P < 0.05). 
Calculating a ROC curve for the use of DHEAS-ratio in the 
diagnostics of ACS gave an AUC of 0.69 (CI 0.58–0.79, 
P < 0.01).
Figure 3 shows that there is a poor agreement between 
the occurrence of low DHEAS and low p-ACTH in both 
patient cohorts. The median s-creatinine level in the 
whole study cohort was 73 µmol/L (39–971). In the ACS 
group, the median level was 72 µmol/L (39–971), and 
in the NFI group 75 µmol/L (40–138). There were no 
significant correlations between DHEAS and s-creatinine, 
whether the cohort was examined in total (Spearman rho 
0.188, P = 0.12) or reviewed as two separate groups 
Dexamethazone suppression testing
The median level of s-cortisol after the LDDST in the ACS 
group was 89 nmol/L (51–517, Table 3). A scatterplot 
comparing s-cortisol results after the overnight DST and 
the LDDST revealed a Spearman correlation coefficient of 
0.812 (P < 0.001).
Urinary-free cortisol
UFC was assayed once (n = 49/58) or twice (n = 29/58) 
in the cohort of ACS. Seven patients had one or more 
positive test results. Two patients tested positive in both 
samplings, while four tested positive in one sample. One 
delivered a single positive urine. The two patients with 
two positive UFC were from the category of patients with 
post-DST-cortisol above 140 nmol/L.
Discussion
Low DHEAS levels have been postulated as a promising 
diagnostic biomarker of ACS (11, 12, 19). Production is 
stimulated by ACTH, but DHEAS has a longer half-life 
than cortisol, which potentially makes it a more stable and 
Figure 1
Proportion of patients with zero (green), one (yellow) and two (red) 
positive saliva samples, respectively, in the NFI group and the ACS group. 
Only patients who had two saliva samples analysed were included in  
this graph.
Figure 2
ROC curve of DHEAS.
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reliable marker of cortisol excess. However, we find that 
DHEAS cannot be trusted as a biomarker of ACS. Neither 
a previously suggested cutoff (11), nor ratio (12) derived 
from studies using the exact same DHEAS assay as we, were 
useful to discriminate between ACS and NFI. ROC analysis 
revealed a fairly good AUC of 0.76 for ACS. Although 
the diagnostic performance of DHEAS in our hands was 
similar to the original study by Yener, sensitivity of 58% 
and specificity of 80% is not convincing. Furthermore, 
our ROC-curve did not indicate another cutoff for DHEAS 
that would have improved the separation of ACS patients 
from healthy subjects.
The use of p-ACTH in the diagnostics of ACS is 
challenged by falsely high values in samples with low 
p-ACTH in some cases (9, 10). There are also challenges 
related to the sampling as p-ACTH is an unstable analyte 
needing immediate freezing.
When evaluating the use of DHEAS in the diagnostics 
of ACS there are several challenges. The current diagnostic 
criteria of ACS may be based on insufficient and uncertain 
data. ACS patients overlap clinically, radiologically as well 
as biochemically with the general population. Without a 
clearly defined group of patient with ACS identified by 
optimal gold-standard diagnostic test, it is likely that the 
conclusions are influenced by patient selection. The use of 
different inclusion criteria and cutoffs in different studies 
adds to the confusion. The optimal study design should 
include endpoints defining improvement of comorbid 
conditions (diabetes mellitus, hypertension, obesity) or 
mortality data after surgery. Furthermore, many patients 
with ACS are quite old, an age group expected to have 
physiologically low DHEAS levels. 
DHEAS as a sulphate conjugate is excreted through 
the kidneys, and higher levels may be expected in 
patients with kidney failure. We found no difference 
between s-creatinine in the two groups, and there were 
no correlation between s-creatinine and DHEAS in the 
whole cohort, or when each patients group were reviewed 
separately. Thus, it is unlikely that our findings are 
confounded by kidney function.
The activity of enzymes involved in the sulphation 
of DHEA to DHEAS may vary between individuals and 
increase variability; thus DHEA could perhaps be a 
substitute. However, assay of DHEA with its shorter half-
life and circadian variation is not straight forward.
Furthermore, the manufacturer does not state any 
known interference issue and we are not aware of any 
such reports, other than heterophilic autoantibodies, 
concerning the Immulite 2000 DHEAS analysis. This may 
be expected because DHEAS are present in blood at levels 
orders of magnitude higher than other steroid hormones.
Sa-cortisol has high diagnostic accuracy (sensitivity 
92–100%, specificity of 93–100%) in the diagnosis of 
overt CS (20). However, the method is not validated for 
low-grade ACS. Our results show that the test is useless 
to differentiate between ACS and NFI. The median value 
in both groups was below the proposed cutoff level, and 
the majority of those with ACS were, based on saliva 
Figure 3
ACTH and DHEAS levels in patients with NFI and with ACS.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-20-0419
https://ec.bioscientifica.com © 2020 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 12/21/2020 09:12:34AM
via University of Bergen Library
G A Ueland et al. Diagnostics of autonomous 
cortisol secretion
9699:10
measurements, categorised as healthy. Only 9/55 of 
the ACS patients tested positive in both saliva samples. 
Another problem with sa-cortisol is a large number of false 
positives in the NFI group (15/51 had at least one positive 
sample). Although these numbers are discouraging, 
one might speculate whether false positives in the NFI 
group could represent a low degree of hypercortisolism 
in some cases. Ceccato et  al. found that the circadian 
cortisol rhythm was not impaired using serial sa-cortisol 
samples and calculating AUCs. The cortisol exposure was 
only increased in the morning in patients with ACS (21). 
This corroborates our findings that late-night sa-cortisol 
is unsuitable as a diagnostic tool in ACS. Our attempt to 
define an alternative cutoff level for sa-cortisol suitable to 
distinguish between NFI and ACS, did not reveal a cutoff 
level with a better sensitivity and specificity than 2.8 
nmol/L used to diagnose overt CS.
The LDDST has mainly been used in a further 
assessment of patients with positive overnight DST, when 
there are discrepancies between the overnight DST and 
other diagnostic tests. After excluding patients with low 
dexamethasone bioavailability, we found a very strong 
correlation between the overnight DST and LDDST. The 
LDDST was not able to exclude ACS in any patients 
diagnosed by DST. Thus, we found no support for the 
continued use of LDDST in the diagnostics of ACS.
The UFC-test has been considered the gold standard in 
the diagnostics of overt CS since the 1970s (22), but have 
shown poor sensitivity for low-grade hypercortisolism 
(23). Our study supports this finding as only seven 
of the 83 patients in the ACS group had one or more 
positive UFC.
Despite the fact that we here report findings in a 
sizeable cohort of subjects, the retrospective nature of the 
study is an important limitation. Furthermore, a significant 
amount of missing data for both DHEAS, sa-cortisol and 
UFC and p-ACTH is an important shortcoming. Also, two 
salivary cortisol samples were only available for 55/83 ACS 
and 51/82 NFI patients – which given the well-recognised 
limitations of a single salivary cortisol measurements, is a 
weakness worth mentioning.
In conclusion, we recognise that the conventional 
approach using spot measurements, dynamic testing 
and daily hormone excretion are far from suitable to 
accurately diagnose ACS. DHEAS was not found to be an 
adequate replacement for p-ACTH in the diagnostics of 
ACS. Late-night sa-cortisol was not useful to distinguish 
between ACS and NFI, and the LDDST did not increase 
the diagnostic specificity compared to the 1 mg overnight 
DST. The UFC had insufficient sensitivity for detecting 
patients with ACS. Thus, for the time being, morning 
ACTH and the 1 mg overnight DST are the tests of choice.
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